Beam Therapeutics (MEX:BEAM) Accumulated Depreciation: MXN-1,829 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
66 GF Score
Price MXN454.00
GF Value MXN408.33
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Accumulated Depreciation?

Beam Therapeutics MEX:BEAM 66 Accumulated Depreciation is MXN-1,829 Mil as of Jun. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN408.33 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Beam Therapeutics's quarterly accumulated depreciation increased from Dec. 2025 (MXN-1,695 Mil) to Mar. 2026 (MXN-1,798 Mil) and increased from Mar. 2026 (MXN-1,798 Mil) to Jun. 2026 (MXN-1,829 Mil).

Beam Therapeutics's annual accumulated depreciation increased from Dec. 2023 (MXN-852 Mil) to Dec. 2024 (MXN-1,504 Mil) and increased from Dec. 2024 (MXN-1,504 Mil) to Dec. 2025 (MXN-1,695 Mil).

Beam Therapeutics Accumulated Depreciation Related Terms

Beam Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Accumulated Depreciation Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only -329.89 -588.19 -851.80 -1,503.84 -1,694.82

Beam Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,566.08 -1,625.31 -1,694.82 -1,798.44 -1,828.81
MEX:BEAM
66GF Score
Beam Therapeutics Inc MEX:BEAM
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of MXN-1,829 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Accumulated Depreciation of MXN-1,829 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Accumulated Depreciation too high?
Beam Therapeutics' current Accumulated Depreciation is MXN-1,829 Mil. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Accumulated Depreciation compare to KOD and TARS?
Beam Therapeutics' Accumulated Depreciation of MXN-1,829 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Accumulated Depreciation is MXN-1,829 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN408.33, compared to a current price of MXN454.00 — trading 11.2% above its estimated fair value. The current Accumulated Depreciation is MXN-1,829 Mil. Beam Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Accumulated Depreciation is MXN-1,829 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN454.00 is trading 11.2% above its estimated GF Value™ of MXN408.33. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Accumulated Depreciation: MXN-1,829 Mil
  • GF Value™: MXN408.33 vs. price of MXN454.00 (11.2% above fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score

Get the complete analysis for MEX:BEAM

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.00
Price
MXN408.33
GF Value